Blog post!

Potential Research Areas Applicable to Early Stage Clinical Trials

By Riya Muckom

Rahul Aggarwal, MD, assistant clinical professor at UCSF, specializes in developmental therapeutics and genitourinary malignancies. During his presentation on Early Stage Clinical Trials, he began outlining the scope of the research involved in the pre-clinical studies of a therapeutic/device intended for human use. Aspects of a potential small molecule therapeutic that need to be understood before starting clinical trials are: physical & chemical properties, pharmacodynamics & efficacy (with in vitro proliferation assays and in vivo xenograft models), pharmacokinetics & metabolism (absorption and distribution of molecule), and toxicology (typically performed on animal models). An interesting development in the field is the shift toward quantifying an “Optimal Biological Dose,” rather than a “Maximum Toxicity Dose” the former being a more relevant measurement in biological systems. Inspired by the increases in computational power, a potential area of research in this field involves developing an algorithm to predict the preclinical results of a potential therapeutic based on prior knowledge of molecular structure and similarly tested molecules. Aggarwal shared his work on molecular imaging biomarkers with the vision that they can one day be used in humans as a screening technique to determine the virulence of a tumor and whether or not treatment is required. These biomarkers are an example of a non-therapeutic technology that must undergo clinical trials to be translated from bench-side to bedside.

Posted in blog
Potential Research Areas Applicable to Early Stage Clinical Trials
  • By Riya Muckom Rahul Aggarwal, MD, assistant clinical professor at UCSF, specializes in developmental therapeutics and genitourinary malignancies. During his

Designing smart and affordable medical technology
  • by Stephen Wilson Paul Yock from Stanford medical school/Biodesign gave a talk recently on the future of medical technology. Back

Delivering cancer treatment via the cerebrospinal fluid
  • by Ioannis Mountziaris This summerizes a talk by Dr. James Rubenstein, MD, PhD Brain cancer serves up a challenge for

Circumventing the Blood-Brain Barrier
  • by Peyton Shieh Prof. James Rubenstein spoke today on “Drug Delivery to the Central Nervous System”. He is a physician-scientist